

Supplementary Figure 1

Scheme of treatment

A




- ↓ murine anti-PD-1, [RMP1-14]
- ▲ CXCR4 antagonist (Pep R)

B



- ↓ Human anti-PD-1, nivolumab
- ▲ CXCR4 antagonist (Pep R54)

Supplementary Figure 2



Supplementary Figure 3

A


CTRL

nivolumab


Pep R54

nivolumab + Pep R54

H&E




MART-1 [A103]



B

P-ERK



Ki-67

